Analysts Set USANA Health Sciences, Inc. (NYSE:USNA) Price Target at $73.67

Shares of USANA Health Sciences, Inc. (NYSE:USNA) have earned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $73.67.

A number of analysts recently issued reports on USNA shares. Pivotal Research reissued a “buy” rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th. Jefferies Financial Group started coverage on USANA Health Sciences in a research report on Thursday, August 22nd. They set a “hold” rating and a $65.00 price objective for the company. Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price objective for the company in a research report on Saturday, October 26th. Finally, ValuEngine raised USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

In other USANA Health Sciences news, Director Robert Auciaux sold 4,018 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $71.87, for a total value of $288,773.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joshua Foukas sold 1,115 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $74.53, for a total value of $83,100.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,385 shares of company stock valued at $617,279. Insiders own 42.50% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of USANA Health Sciences by 1.7% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 8,925 shares of the company’s stock worth $709,000 after buying an additional 150 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of USANA Health Sciences by 91.7% in the third quarter. Tower Research Capital LLC TRC now owns 648 shares of the company’s stock worth $44,000 after buying an additional 310 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of USANA Health Sciences in the second quarter worth about $27,000. LS Investment Advisors LLC acquired a new stake in shares of USANA Health Sciences in the second quarter worth about $32,000. Finally, Strs Ohio lifted its position in shares of USANA Health Sciences by 7.7% in the second quarter. Strs Ohio now owns 9,800 shares of the company’s stock worth $778,000 after buying an additional 700 shares during the last quarter. 63.53% of the stock is owned by institutional investors.

Shares of USANA Health Sciences stock traded up $0.53 during midday trading on Tuesday, hitting $75.81. The company’s stock had a trading volume of 65,162 shares, compared to its average volume of 241,363. The firm has a market capitalization of $1.68 billion, a P/E ratio of 14.69 and a beta of 0.28. The stock has a 50-day simple moving average of $71.01 and a 200-day simple moving average of $71.52. USANA Health Sciences has a 1-year low of $58.30 and a 1-year high of $125.61.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, October 22nd. The company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $0.22. The firm had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $256.22 million. USANA Health Sciences had a return on equity of 27.60% and a net margin of 9.38%. The business’s revenue for the quarter was down 12.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.24 earnings per share. On average, analysts forecast that USANA Health Sciences will post 3.99 EPS for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Featured Story: What is an inverted yield curve?

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.